Zoono (ASX:ZNO) is a global biotech company that develops, manufactures and distributes a suite of scientifically-validated, long-lasting and environmentally-friendly antimicrobial solutions. Zoono’s mission is to improve health and well-being through innovative, safe, non-toxic and durable germ protection. Zoono produces sprays, wipes and foams suited for skin care, surface sanitisers, and mould remediation treatments. The products are based on the ‘zoono molecule’, a unique antimicrobial molecule that bonds to any surface and kills pathogens including bacteria, viruses, algae, fungi and mould. Zoono’s products have received numerous regulatory approvals and the company’s technology claims are supported by independent testing conducted in laboratories worldwide. Zoono is headquartered in New Zealand and its products are available globally. To learn more, please visit: www.zoono.com
Looking for a particular Zoono Global employee's phone or email?
The Zoono Global annual revenue was $11.8 million in 2026.
Barry Woolcott is the CEO of Zoono Global.
13 people are employed at Zoono Global.
Zoono Global is based in Auckland, Auckland.
The NAICS codes for Zoono Global are [212, 21311, 21, 213, 2131].
The SIC codes for Zoono Global are [14, 148].